Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Rigel Pharmaceuticals stock | $3.72
Learn how to easily invest in Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals, Inc is a biotechnology business based in the US. Rigel Pharmaceuticals shares (RIGL) are listed on the NASDAQ and all prices are listed in US Dollars. Rigel Pharmaceuticals employs 169 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Rigel Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – RIGL – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
Rigel Pharmaceuticals stock price (NASDAQ: RIGL)Use our graph to track the performance of RIGL stocks over time.
Rigel Pharmaceuticals shares at a glance
|Latest market close||$3.72|
|52-week range||$2.14 - $5.50|
|50-day moving average||$4.24|
|200-day moving average||$3.93|
|Wall St. target price||$8.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.35|
Buy Rigel Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Rigel Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Rigel Pharmaceuticals price performance over time
|1 week (2021-07-22)||N/A|
|1 month (2021-07-02)||-15.65%|
|3 months (2021-04-30)||3.72|
|6 months (2021-01-29)||N/A|
|1 year (2020-07-29)||N/A|
|2 years (2019-07-29)||N/A|
|3 years (2018-07-29)||N/A|
|5 years (2016-07-29)||N/A|
Rigel Pharmaceuticals financials
|Revenue TTM||$133.9 million|
|Gross profit TTM||$47.6 million|
|Return on assets TTM||-2.87%|
|Return on equity TTM||-14.65%|
|Market capitalisation||$696 million|
TTM: trailing 12 months
Shorting Rigel Pharmaceuticals shares
There are currently 20.8 million Rigel Pharmaceuticals shares held short by investors – that's known as Rigel Pharmaceuticals's "short interest". This figure is 3.6% down from 21.6 million last month.
There are a few different ways that this level of interest in shorting Rigel Pharmaceuticals shares can be evaluated.
Rigel Pharmaceuticals's "short interest ratio" (SIR)
Rigel Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Rigel Pharmaceuticals shares currently shorted divided by the average quantity of Rigel Pharmaceuticals shares traded daily (recently around 1.7 million). Rigel Pharmaceuticals's SIR currently stands at 12.58. In other words for every 100,000 Rigel Pharmaceuticals shares traded daily on the market, roughly 12580 shares are currently held short.
However Rigel Pharmaceuticals's short interest can also be evaluated against the total number of Rigel Pharmaceuticals shares, or, against the total number of tradable Rigel Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Rigel Pharmaceuticals's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Rigel Pharmaceuticals shares in existence, roughly 120 shares are currently held short) or 0.1228% of the tradable shares (for every 100,000 tradable Rigel Pharmaceuticals shares, roughly 123 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Rigel Pharmaceuticals.
Find out more about how you can short Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals share dividends
We're not expecting Rigel Pharmaceuticals to pay a dividend over the next 12 months.
Have Rigel Pharmaceuticals's shares ever split?
Rigel Pharmaceuticals's shares were split on a 1:9 basis on 24 June 2003. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Rigel Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Rigel Pharmaceuticals shares which in turn could have impacted Rigel Pharmaceuticals's share price.
Rigel Pharmaceuticals share price volatility
Over the last 12 months, Rigel Pharmaceuticals's shares have ranged in value from as little as $2.14 up to $5.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Rigel Pharmaceuticals's is 1.506. This would suggest that Rigel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Rigel Pharmaceuticals overview
Rigel Pharmaceuticals, Inc. , a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co. , Ltd.
Stocks similar to Rigel Pharmaceuticals
Rigel Pharmaceuticals in the news
Were Hedge Funds Right About Rigel Pharmaceuticals, Inc. (RIGL)?
Earnings Preview: Rigel Pharmaceuticals (RIGL) Q2 Earnings Expected to Decline
Rigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update
Frequently asked questionsWhat percentage of Rigel Pharmaceuticals is owned by insiders or institutions?
Currently 0.214% of Rigel Pharmaceuticals shares are held by insiders and 89.005% by institutions. How many people work for Rigel Pharmaceuticals?
Latest data suggests 169 work at Rigel Pharmaceuticals. When does the fiscal year end for Rigel Pharmaceuticals?
Rigel Pharmaceuticals's fiscal year ends in December. Where is Rigel Pharmaceuticals based?
Rigel Pharmaceuticals's address is: 1180 Veterans Boulevard, South San Francisco, CA, United States, 94080 What is Rigel Pharmaceuticals's ISIN number?
Rigel Pharmaceuticals's international securities identification number is: US7665596034 What is Rigel Pharmaceuticals's CUSIP number?
Rigel Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 766559108
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert